{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:05Z","timestamp":1775872265262,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Diffuse cutaneous systemic sclerosis (dcSSc) is a heterogeneous autoimmune disease characterized by progressive skin fibrosis, vasculopathy and variable organ involvement. Our recent case report about this patient described clinical improvement under IL-17A inhibition with secukinumab for worsening of cutaneous involvement after autologous hematopoietic stem-cell transplantation. We present the extended disease course through 2025. In July 2025 the patient presented with a new flare characterized by cutaneous tightening, dysesthetic sensory symptoms and intermittent pruritus despite ongoing secukinumab therapy. Given the early signs of renewed cutaneous progression and with the aim of preventing further deterioration, treatment was switched to bimekizumab, a dual IL-17A\/IL-17F inhibitor. By November 2025 the patient demonstrated resolution of cutaneous symptoms, improvement of modified Rodnan skin score and improved joint stiffness. A single adverse event was mild oral candidiasis. This case follow-up suggests that broader IL-17 pathway inhibition may represent a promising therapeutic approach for selected patients with refractory inflammatory cutaneous manifestations of dcSSc.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1771650","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:50Z","timestamp":1773120710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Switching secukinumab to bimekizumab in diffuse cutaneous systemic sclerosis after autologous hematopoietic stem cell transplantation: a case follow-up"],"prefix":"10.3389","volume":"17","author":[{"given":"Lea-Kristin","family":"Nagler","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 2, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Labinsky","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Kroi\u00df","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.061","article-title":"Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial","volume":"89","author":"Fukasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2022-eular.2519","article-title":"POS0881 Efficacy and safety of subcutaneous brodalumab, a fully human anti\u2013IL-17RA monoclonal antibody, for systemic sclerosis with moderate-to-severe skin thickening: a multicenter, randomized, placebo-controlled, double-blind phase 3 study","volume":"81","author":"Fukasawa","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294496","article-title":"Case Report: Effectiveness of secukinumab in systemic sclerosis with early skin progress after autologous hematopoietic stem cell transplantation and end-stage kidney disease","volume":"14","author":"Strunz","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1967748","article-title":"Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis","volume":"17","author":"Ali","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-022-01084-4","article-title":"Inhibiting IL-17A and IL-17F in rheumatic disease: therapeutics help to elucidate disease mechanisms","volume":"24","author":"Tam","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/23971983211039421","article-title":"The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic","volume":"6","author":"Bellando-Randone","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885609","article-title":"The yin and yang of IL-17 in systemic sclerosis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.84738","article-title":"Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis","volume":"15","author":"Robak","year":"2019","journal-title":"Arch Med Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15508","article-title":"Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis","volume":"47","author":"Fukayama","year":"2020","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1002\/acr2.70131","article-title":"Autologous hematopoietic stem cell transplantation in systemic sclerosis: current evidence and future directions","volume":"7","author":"Sieiro Santos","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152638","article-title":"Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study","volume":"71","author":"Spierings","year":"2025","journal-title":"Semin Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941011","article-title":"Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis","volume":"13","author":"Kawashima-Vasconcelos","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00834","article-title":"Natural killer cells regulate th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis","volume":"9","author":"Darlington","year":"2018","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:50Z","timestamp":1773120710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2026.1771650"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771650","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1771650"}}